SARS-CoV-2 vaccination is the standard of care for the prevention of COVID-19 disease.
Although vaccination triggers both humoral and cellular immune response, COVID-19 …

The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than
90% of the general population, but its efficacy in transplant recipients remains controversial …

The humoral and cellular immune responses against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) upon the coronavirus disease 2019 (COVID-19) vaccination …

Novel mRNA-based vaccines have been proven to be powerful tools in combating the
global pandemic caused by SARS-CoV-2, with BNT162b2 (trade name: Comirnaty) …

Objectives The recent surge in coronavirus disease 2019 cases led to the consideration of a
booster vaccine in previously vaccinated immunosuppressed individuals. However, the …

In this prospective observational cohort study we analyzed cellular and serological immune
response parameters against SARS-CoV-2 and current variants of concern (VOC) in 147 …

Humoral immunity after SARS-CoV-2 immunization or natural infection is thought to be
evanescent. In our study, we aimed to longitudinally characterize the kinetics of antibody …

Background Since the introduction of various vaccines against SARS-CoV-2 at the end of
2020, infection rates have continued to climb worldwide. This led to the establishment of a …

Two KTRs presented with symptomatic COVID-19 67 and 72 days, respectively, after the
third vaccine injection. One KTR was hospitalized but did not require intensive care. Both …

Mass SARS-Cov-2 vaccination campaign represents the only strategy to defeat the global
pandemic we are facing. Immunocompromised patients represent a vulnerable population at …